MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Sarepta Therapeutics Inc

Fechado

SetorSaúde

62.4 0.71

Visão Geral

Variação de preço das ações

24h

Atual

Mín

60.58

Máximo

64.16

Indicadores-chave

By Trading Economics

Rendimento

125M

159M

Vendas

191M

658M

P/E

Médio do Setor

27.274

63.778

EPS

1.9

Margem de lucro

24.156

Funcionários

1,372

EBITDA

138M

187M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+164.8% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.8B

6.8B

Abertura anterior

61.69

Fecho anterior

62.4

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Sarepta Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2025, 14:19 UTC

Grandes Movimentos do Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 de jun. de 2024, 23:05 UTC

Grandes Movimentos do Mercado

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 de jun. de 2024, 08:58 UTC

Principais Notícias

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Sarepta Therapeutics Inc Previsão

Preço-alvo

By TipRanks

164.8% parte superior

Previsão para 12 meses

Média 165.42 USD  164.8%

Máximo 215 USD

Mínimo 75 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Sarepta Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

16

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

61.525 / 72.17Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.